Otros idiomas Sage Therapeutics, Inc.

Acciones

SAGE

US78667J1088

Tiempo real estimado Cboe BZX Otros sitios de cotización 19:19:32 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
14,2 ^USD	+0,11 %		+9,50 %	-34,56 %

26/04	SAGE THERAPEUTICS, INC. : Truist Securities se mantiene neutral, sin recomendación.	ZM
25/04	Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE	28/04
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q1 Revenue $7.9M, vs. Street Est of $5.2M	25/04
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress	25/04
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinson's disease	18/04
Top Midday Decliners	17/04
Sector Update: Health Care Stocks Advance Premarket Wednesday	17/04
Sector Update: Health Care	17/04
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	17/04
Top Premarket Decliners	17/04
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint	17/04
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease	17/04
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease	17/04
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024	11/04
Sage Therapeutics : Announces Dr. Steve Paul to Retire from Board of Directors	26/03
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board	26/03
Sage Therapeutics to Present at Upcoming March Investor Conferences	28/02
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	14/02
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines	14/02
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Sage Therapeutics, Inc.

Acciones

SAGE

US78667J1088

Otros idiomas

Filtros